

Registered in England and Wales
Company Number 3963360

THE ORCHID CANCER APPEAL
'ORCHID'
ANNUAL REPORT AND ACCOUNTS
FOR THE YEAR ENDED 30 JUNE 2009
Charity Number 1080540

THE ORCHID CANCER APPEAL
INDEX TO THE ANNUAL REPORT AND ACCOUNTS

	Page
Title page	1
Index to the Annual report and Accounts	2
Company information	3
Report of the Board of Trustees	4
Structure, Governance and Management	4
Objectives and Activities	5
Financial Review	15
Future Plans	16
Formal Statements	17
Auditor's Report	18
Statement of Financial Activities	19
Balance Sheet	20
Notes to the Financial Statement	21

THE ORCHID CANCER APPEAL

COMPANY INFORMATION

for the year ended 30 June 2009

Registered with the Charity Commission on 3rd May 2000

Company Limited by Guarantee

Charity Number 1080540

Incorporated in England Number 3963360

REGISTERED OFFICE	St. Bartholomew's Hospital London EC1A 7BE
BOARD OF TRUSTEES	Mr R S Broadhurst CBE (Chairman) Mr R J O Barton (Treasurer) His Honour G Boal QC The Rt Hon Lord Fellowes Mr C S Osborne Mr S Seymour Mr S Raby Mr D Badenoch Mr P Norman Professor RTD Oliver Mr R Lane Ms D Selby
CHIEF EXECUTIVE	Mr A J D Somerville (resigned 4 February 2009) Miss R I Porta (appointed 9 February 2009)
AUDITORS	Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD
ACCOUNTANTS	JS2 Ltd 1 Crown Square Woking Surrey GU21 6HR
LEGAL ADVISORS	Farrer & Co 66 Lincoln's Inn Fields London WC2A 3LH
BANKERS	HSBC Plc. 20 Electric Parade George Lane South Woodford London E18 2LX CAF Bank Ltd 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ COIF Charity Funds 80 Cheapside London EC2V 6DZ Birmingham Midshires Pendeford Business Park Wobaston Road Wolverhampton WV9 5HZ

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

The Trustees who are also directors of the charitable company present their report for the period for the year ended 30 June 2009, together with the accounts covering the same period. Company Information is included as page 3.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Duly registered as a charity, The Orchid Cancer Appeal ('Orchid') is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association. Its principal activity is to increase public awareness, and to improve and simplify the treatment of men's cancers, including the funding of research into diagnosis, prevention and treatment of male cancer.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chairman's aim to maintain a balanced composition. In line with this policy, two new trustees were elected during the year to provide a still broader range of expertise and experience. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meets routinely four times every year, and at each Annual General Meeting, one third of the Trustees (or the nearest number thereto) retires from office in rotation, in order of longevity of appointment. If the ensuing vacancy is not filled, the retiring Trustee may be reappointed.

Trustee training and induction

On appointment, Trustees will receive an induction pack that includes the following:

- a copy of the Memorandum and Articles of Association
- a brief summary of the charity's history and significant events in its history
- the Annual Report for the last two years and the most recent sets of management accounts
- the minutes of the most recent meetings of the Board of Trustees and Scientific Advisory Board (SAB).
- Board papers outlining finance procedures, peer review, and grants & awards policy
- information to appraise them of the duties and responsibilities in accordance with App. 3 of ICSA guidance

In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of charity and/or medical research issues. Trustees have availed themselves of these opportunities during the year.

Structure, delegation and decision-making

Orchid is committed to attracting and retaining talented staff. During the year 2 new senior appointments were made to support the development of the fundraising and awareness functions - a Director of Marketing and a Trusts and Statutory Fundraising Manager. The specialist healthcare agency, SPINK PR were also engaged to support Orchid's diverse media activities following the relocation overseas of Mushroom Media PR. Temporary and volunteer personnel were engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising. After 5 years service, Mr Angus Somerville, Chief Executive left Orchid in February. A review of the senior management team was undertaken and the Director of Marketing was appointed to the role of Chief Executive. The new postholder, Miss Rebecca Porta has held senior appointments within a range of healthcare charities for over 17 years.

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee, comprising the Honorary Treasurer, Mr J Barton, as Chair, Mr R Broadhurst, Mr C Osborne and Mr S Seymour (appointed September 2009), continues to supervise Orchid's financial and general management, and presents a report to the Board each quarter.
- Four new Sub-Committees were established during the year to enable Trustees to apply their expertise and interest more effectively in support of the charity's operational activity. These are the Business Development Sub-Committee, Events Sub-Committee, Projects Sub-Committee and Major Donor Sub-Committee. The Committees aim to meet twice a year or quarterly as required

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

- At the operational level, the Board delegates the day-to-day running of the charity to the Chief Executive, requiring her to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. In normal circumstances, the Board is kept apprised of personnel, awareness, the research programme and budgetary issues.

Research Programme:Peer Review

Given the importance of expert independent peer review in validating applications for research grants and the verification of outcomes, the Scientific Advisory Board (SAB) provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the charity currently funds or may consider funding. The SAB comprises both scientific and clinical members from across the international research community. In accordance with best practice, all SAB members have been approached during the year to establish their continued willingness to serve. One member, Professor Freddie Hamdy resigned due to increased commitments and a new member is being sought. The Board of Trustees thanks Professor Freddie Hamdy for his support and guidance. The SAB's fifth report was presented to the Board of Trustees in March 2009 by its Chairman, Professor Norman Maitland, and again provided essential guidance to the Board when it considered its award of future research grants for the financial year 2010/11. The report was highly complimentary about the results of the key research disciplines, and congratulated four programme leaders on the results achieved in the previous year. The Board wishes to thank the SAB members for giving their time and expertise to the charity, and to Professor Maitland, in particular, for providing advice to programme leaders in relation to their work.

Internal control and risk management

Orchid has an annual planning and budgeting process which is approved by the Finance Committee and Board of Trustees. The process is based on a review of performance, the external environment, future trends and corporate objectives. As part of this process the Finance Committee and Board of Trustees examine the major strategic, business and operational risks which the charity faces and confirm that necessary systems have been established to identify, evaluate, manage (and not eliminate) these risks. The risk management plan is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

OBJECT AND ACTIVITIES FOR THE PURPOSE OF PUBLIC BENEFIT

Object

The objectives of the charity are to raise funds for scientific and clinical research into prostate, testicular and penile cancers, and to promote awareness and education about these diseases.

Public Benefit

The Trustees confirm that they have complied with the duty in section 4 of the Charities Act 2006 to have due regard to the Charity Commission's general guidance on public benefit.

Vision

The charity's vision is to promote greater knowledge and awareness about male specific cancers by:

- funding integrated scientific and medical research into prevention, diagnosis and treatment of these diseases, and
- providing eye-catching, easy to understand information about them to men and women throughout the UK, thereby helping to ensure a better quality of life or even life itself for those affected. We aim to reach as many individuals as possible by providing support and information free of charge. In doing so, Orchid aims to become the leading UK male cancer charity.

Operating context

Last year over 37,000 men in the UK were diagnosed with a male specific cancer. And sadly these numbers are expected to increase. Now, more than ever before, Orchid needs to continue its investment in a dedicated programme of research to help improve our understanding of these cancers and find new ways to treat and manage them. Alongside this research programme, better education and awareness of the signs and symptoms of these cancers is needed – an early diagnosis and treatment can make a real difference, helping to save men's lives.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

Orchid is proud of its many achievements during the year and has supported people affected by or interested in male cancer through a range of services, awareness raising and a high quality research programme. This was made possible in part due to strong fundraising performance across key areas despite the current financial climate. Events have once again played a significant role in generating funds and enhancing the charity's profile. 2008/09 has seen the most successful events programme to date with Marathons, cycle rides and a bespoke overseas trek raising considerable funds alongside those events organised by individuals.

The appointment of a Director of Marketing to work alongside Mushroom Media PR and SPINK PR has resulted in increased media interest in male cancer and the work of Orchid. The charity has been proactive in commenting on research developments, health campaigns, topical issues and case studies. Two dedicated awareness campaigns were developed during the year. The first annual Orchid Male Cancer Awareness Week was launched from 20 - 26 April 2009. The campaign achieved considerable media coverage with an estimated 18.2 million "opportunities to see" Orchid. A testicular cancer campaign with The Sun newspaper and direct response agency EHS Brann to coincide with the World Cup qualifier between England and Kazakhstan was launched in October. The campaign attracted over 11,046 visitors on The Sun website and 3,700 to the YouTube video and was recently named "one of the four best campaigns right now" in Contact magazine.

Increased awareness and interest in male cancer and the work of Orchid has resulted in more enquires from a wide range of stakeholders. Ensuring we are well placed to respond to their needs is a priority for the charity. During the year new sections were introduced to the Orchid website and a Media Centre was launched to provide up to the minute information for media. An Editorial Board, comprising healthcare professionals, carers and people diagnosed with male cancer has been recruited to help develop and deliver a series of specialist Factsheets to complement the existing portfolio of publications. Members of the Board will also input into future services. Staff attended information days and awareness events at companies, schools and colleges and spoke at conferences. Increasingly, Orchid is invited to input into service development – in May the Chief Executive was invited to give evidence to a review being undertaken by the Newham Health Scrutiny Committee into prostate and testicular cancer services.

The Orchid funded research programme has once again produced impressive results. The Chairman of the SAB concluded the research teams had made considerable progress since last year. The research teams have also contributed to developing Orchid's information products and frequently support media activities by providing interviews or acting as spokespeople. The Board of Trustees is grateful for their ongoing support in this area.

Orchid continues to demonstrate its commitment to collaborate with other representative groups. Its most significant involvement is through its work with the Prostate Cancer Charter for Action, an influential collaborative of 24 not-for-profit and professional organisations, whose lobbying has resulted in important advances in prostate cancer care by the Department of Health (DH). Orchid is also playing a full part in Cancer 52, an equivalent collaborative concerned with less common cancers (ie all those except prostate, lung, breast and bowel disease) that together account for around 52% of all cancer deaths in the UK. Other areas of involvement include the Cancer Campaigning Group and the Men's Health Forum.

Targets and progress

The following targets were identified for 2008/09 and thanks to our supporters, friends, staff, research teams, volunteers and partners we are pleased to report progress in each of these areas:

- Support research activity, as advised by the SAB, to ensure the quality and value for money of the translational scientific and clinical programmes, in collaboration with Barts and the London School of Medicine/NHS Trust.

Progress: the research teams have continued to do well and achieved impressive results.

- Secure support to enable two new research projects.

Progress: in June Orchid awarded grants in 4 areas of research: basic science in molecular therapeutics, carcinogenesis, histopathology, and clinical trials.

- Implement the co-funding of the Chair of Male Genito-Urinary Oncology in the ECMC, with the BLC.

Progress: the appointment is behind schedule but a recruitment panel has been confirmed and the recruitment process commenced in autumn 2009.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

- Secure funding to establish a dedicated telephone service or equivalent facilities to provide information and support in relation to penile cancer.

Progress: working with St Georges Hospital, Tooting and Macmillan Cancer Relief, Orchid secured support for a penile cancer support and information day to be held in September 2009. Staff have begun working with selected Penile Cancer Supra-Networks to identify the information needs of patients, carers and healthcare professionals. New publications and specialist Factsheets are planned for release in 2010.

- Recruit the necessary personnel to enable Orchid to generate the required level of income and charitable activity.

Progress: the appointment of a senior Director of Marketing and a Trust and Statutory Fundraising Manager to the team has helped to identify and develop opportunities ensuring strong, sustainable fundraising performance to enable the charity to meet its existing and future commitments. Mushroom Media and SPINK PR have helped raise awareness of male cancer and Orchid through increased media activities including dedicated campaigns such as the first Orchid Male Cancer Awareness Week, promotion of events and supporter activities.

- Increase the distribution of information and awareness material by 10% from 2007/08 levels, as part of enhancing our audience reach.

Progress: over 22,000 publications, 4,000 awareness posters and 25,000 testicular cancer information wallet cards were distributed free of charge during the year - an increase of 90%, 50% and 60% respectively on the previous year. A further 1,220 free DVD resource packs on testicular cancer were sent to school nurses, youth offending institutes and pupil referral centres.

A postcard campaign to raise awareness of male cancer was developed and 40,000 postcards distributed to companies, sports centres, GP surgeries, hospitals and individuals supporters. The postcard campaign has proven successful and a new campaign is underway.

As part of our continued commitment to developing services for people affected by or interested in male cancers, a series of specialist Factsheets have been developed to complement the existing portfolio of publications. These include Testicular Cancer : HIV and Testicular Cancer, Diet : Vitamin D and Prostate Cancer, Prostate Cancer : The Big Question, Prostate Cancer : The Familial Link and Male Cancer, Diet and Lifestyle. The free in-house magazine, low-down was relaunched to ensure it appealed to a wider audience. An Editorial Board, comprising patients, carers and healthcare professionals has also been recruited to support the development and delivery of new publications and specialist Factsheets. In4Health who produce adverts for plasma screens in GP waiting rooms developed an Orchid "animated" advert which was shown in GP surgeries within Wiltshire PCT. We are particularly pleased that our database of healthcare professionals and education professionals has increased to over 2000, double the previous year.

The first annual Orchid Male Cancer Awareness Week was developed and launched from 20 -26 April 2009. During the Week Orchid launched new data into awareness of male cancers. A survey commissioned through leading market research agency, GfK NOP, which interviewed 824 adults aged 16 and over in the UK revealed:

- One in three men (33%) said they're more knowledgeable about breast cancer compared to one in ten (10%) who were familiar with the signs and symptoms of testicular cancer.
- Prostate cancer is the most common male cancer, accounting for 24% of men's cancer cases, but one in five (21%) men and women admitted they don't know anything about it.
- One in six men surveyed (14%) thought prostate cancer could affect women.
- Three quarters of UK men (73%) recognised that a lump in the testes could be a sign of testicular cancer – but one in four (25%) still never checked their testes. Nearly one in three (30%) were not even aware they can check themselves for lumps. This is in stark contrast to women, who were more likely to take their health in their own hands - only 7% of them say they didn't check their breasts.
- One in four people surveyed (23%) had a family member or close friend with testicular or prostate cancer.

The campaign achieved considerable media coverage with an estimated 18.2 million "opportunities to see" Orchid. The Week was also featured on a number of websites for healthcare professionals and information days and events were held at companies.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

October saw the launch of a festive cancer campaign with The Sun newspaper and direct response agency EHS Brann to coincide with the World Cup qualifier between England and Kazakhstan. A team of young men, dressed in manikinis and supported by a host of celebrities including Heart FM's Toby Anstis raised awareness of the disease. The campaign attracted over 11,046 visitors on The Sun website and 3,700 to the YouTube video. Our sincere thanks to The Sun and EHS Brann for their support.

- Develop the Orchid website to meet and deliver the needs of a range of stakeholders.

Progress: during the first full year of operation, over 33,000 people visited the website and 166,800 pages were viewed. New sections were introduced and a Media Centre was launched to provide up to the minute information for media. In response to visitor feedback we ensured navigational issues were addressed and introduced easier systems for ordering.

- Build the charity's presence in cycling and running events, while rigorously scrutinising the return on investment, and conduct a successful Kilimanjaro challenge trek.

Progress: income from Orchid's events programme has been the most successful to date reflecting the commitment and hard work of our many supporters and staff. Orchid has maintained its investment in places and promotion in the London, New York, Chicago and Berlin World Marathon and other running events. Cycling events have continued to prove popular and the ninth annual charity bike ride, Orchid Cycle Essex, was the most successful ever. The charity's first bespoke trek to Kilimanjaro in June raised over £70,000. Increased awareness of male cancer and Orchid has resulted in more events organised by individuals. Over £230,000 has been raised by our generous supporters.

- Secure funding to recruit a research information officer, to conduct research grant and SAB administration, and act as the charity's spokesperson in relation to matters of research and awareness with the general public/media etc.

Progress: recruitment for an honorary post of research information officer will commence in 2010. A dedicated nurse post is seen as a priority at the present time.

- Re-engage with the AMRC to establish the protocols involved with membership for single institution research funding and, depending on the outcome, negotiate full or associate membership as appropriate.

Progress: this has not been achieved. Existing research commitments and staff changes have not enabled this to progress further. This will need to be reviewed in 2009-10.

Research

Orchid-funded research has once again made significant strides in the past year. The 5th Annual Report reflected a general opinion that much progressive work had been carried out across all areas. The following reports were received:

Dr Daniel Berney

Consultant and Honorary Reader, GU pathology.
Institute of Cancer Barts & The London School of Medicine, QMUL

Aims of the Tissue Bank Team

- Collection and management of the genito-urinary tissue bank, ensuring validation of the tissue, ethical collection of tissue and storage.
- Construction of tissue micro arrays for future research.
- Distribution to the end user groups of validated material.
- Basic pathological and molecular research.
- Collaboration with other genito-urinary groups in the UK/world

Key Achievements

- Fifteen peer-reviewed publications in 2008 or in press.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

- Trans-Atlantic Prostate Group papers
- Testis Papers
- The first penile paper from the group
- Successful CRUK TRICC grant application for prostate research
- First two papers from The European Network of uro-Pathologists (ENUP)
- Collaboration with The Royal Marsden.
- Continuing penile work presented at IAP
- Continued collection/distribution of prostate and testis.
- Work on extraction of prostate carcinoma cells from blood in collaboration with Orchid clinical trial group
- Translational work on TAPG
- Invited speaker at IAP on testis and Invited speaker to Egypt
- Secretary of The British Association of Urological Pathologists (BAUP).
- Associate editor of Histopathology
- Appointed on 2 NCRU committees (Testis and translational)
- Collaboration on RC pathologists prostate pathology guidelines
- RC Pathologists representative to NICE

Testis

- The series of 50 patients with malignant germ cell tumours, over the age of 60 was published in *Modern Pathology* and abstracted for platform presentation at USCAP in March 2007. The paper outlines a series of germ cell tumours diagnosed above the age of 60 and shows that these tumours present at a later stage than those in a younger population.
- Two reviews were published in 2008.
- Have been commissioned to jointly write a chapter on testicular pathology in the prestigious Sternberg's Surgical pathology. This Chapter will appear in late 2009.
- A collaborative new paper on carcinoid tumours of the testis is in preparation.

Penis

- Funding from the Jean Shanks Foundation came on line in April 2007. This has resulted in 1 abstract at USCAP, 2 at the IAP and one published article. Work on the penile array is complete: this is probably the most complete penile tumour series in Europe with over 100 cases. The team also completed PCR experiments into HPV typing in penile tumours. Two further papers are currently being prepared and an abstract accepted for USCAP 2009.

Prostate

- The major thrust of the prostate work has again been with the Trans-Atlantic Group (TAPG).
- A paper on methods of assessing tumour extent in biopsies is in preparation.
- Paper on Ki-67 in the TAPG series is currently being reviewed by the BJC.
- Paper on P53 is in press in BJC.
- Further possible papers on p16, p21 are being considered.
- The papers on the TMPSS/ERG translocation on the TAPG material were published in 2008 in the prestigious journal *Oncogene*. This has resulted in increasing co-operation between Dr Berney and the molecular groups at the Royal Marsden Hospital, especially Professor Cooper, and has resulted in a second paper on the heterogeneity of translocation patterns in the prostate.
- The team obtained in August, the translation CRUK grant, and in the process of collecting the tissue blocks from the different UK hospitals to make the tissue microarray for the end of the year 2009. The collection involved Dr. Bisson and technical research assistants E. Stankiewicz and S. Kudahetti. This will involve considerable work by the whole team to validate and array the material.
- Blood/CTC: Following previous research in collaboration with Dr Prowse and Dr J Shamash, circulating tumours cells are routinely isolated in our lab. Dr. Bisson is involved in cells extraction and coordinated the work between Clinical trial team and researchers.

Tissue Collection and ethics

The Orchid Tissue Bank is registered with the Human Tissue Resource Centre (HTRC), an organisation that centralises and controls the tissue collection in Bart's hospitals. Due to the full implementation of the Human Tissue Act, the team has had to put through a new tissue ethics application, which will allow wider collection of tissue from more hospitals and more scope to use the tissue in other projects. This major undertaking is being led by Dr. Bisson, and the team hoped for approval early in 2009. After the move of the laboratory, the team had to re-organise the tissue collection and included the Standard Operational Protocols, led by Dr. Bisson. This year, the team have extended the distributing of tissue to the following new research projects:

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

- Prostate cancer tissues are distributed for a clinical trial study coordinated by Dr. Norbert Avril and Professor Steve Mather in Institute of Cancer.
- The team is collecting non malignant prostate tissue for a biopharmaceutical company, Scottish biomedical.
- The team continue supplying Dr. YG Lu on tissue and frozen sections for his own ethically authorised study. Tissue from the TAPG is being sent to three biomedical companies, Myriad, Aureon and genomic health in collaborative research to begin in 2009, organised and coordinated by Professor Cuzick.

Dr Jonathan Shamash and Dr Thomas Powles
Senior Lecturers in Medical Oncology
Barts & the London School of Medicine, QMUL. London

Grant aims

- To perform hypothesis based clinical trials with translational components, which will form the basis of national phase III studies.
- To identify markers, either from translational research or data base analysis, to allow prognostication for patients and optimisation of treatment strategies.

Key Achievements

Testis cancer

- In 2003 Orchid sponsored work which described in detail the link between HIV and testis cancer (J Clin Oncol. 2003 May 15;21(10):1922-7). In 2008 the team concluded this work by showing the risk of testis cancer for people with HIV has returned to normal since the introduction of effective drugs to treat HIV. This work was published in the Journal of Clinical Oncology in December 2008.
- In 2008 the team also described the long term risk of osteoporosis in testis cancer survivors. This work suggested that with a median follow-up over 11 years, patients with testis cancer do not seem to be at increased risk of osteoporosis. This work was published in Osteoporosis International – November 2008.
- The work identifying prognostic factors for relapsed testis cancer is coming to fruition. The team have been one of the leading centres (along with Professor Jorg Bayer in Berlin) in the international collaboration, which has collected over 1000 patients with relapsed testis cancer. This was presented at ASCO2009 and has been submitted to the JCO. This work has redefine prognostication of treatment for relapsed testis cancer. This data is currently perhaps the most important world wide in testis cancer. Dr Powles is on the steering committee for this project.
- Preclinical work continues to produce good results. An abstract at AACR investigating lapatinib in combination with chemotherapy was presented in San Francisco in March 2009, and a paper describing the efficacy of oxaliplatin in testis cancer cell lines was published in CCP in 2009 .
- Having defined a poor prognosis group on the basis of the data found on relapsed testicular cancer (raised LDH and/or aged over 35), the team undertook a study to see whether the encouraging results described by the Indiana group using epirubicin and cisplatin could be confirmed. Unfortunately the study (GAMEC-A) closed because of poor efficacy. It was encouraging to note however that the study could be completed rapidly thanks to the referral of patients from throughout the Anglian Germ Cell Cancer Group; the increased number of clinicians participating means that recruitment into future studies is likely to be brisk.
- In metastatic seminoma, the team's phase II study using Carboplatin AUC 10, closed having completed accrual. The paper is now being written up and suggests a cure rate using this approach of 95%. A further study incorporating PET is planned.
- We have commenced a collaboration with the Memorial Sloan Kettering, to investigate molecular markers associated with resistance to cisplatin based therapy from patients with GCT of the testis.

Prostate cancer

- The major achievement of 2008 was the completion of the first phase III randomised controlled study (dexamethasone and aspirin with deferred diethylstilbestrol versus dexamethasone, aspirin and diethylstilbestrol) as initial management in castration-resistant prostate cancer. The data shows that it is possible to delay the stilboestrol safely with reduced toxicity. This data has been sent to the JCO.
- During this period we also identified prognostic factors associated with response to further hormone therapy in castrate resistant prostate cancer. The PSA dynamics are crucial here. This work has been accepted for publication in Cancer.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

Overview of ongoing clinical trials.

- Testis cancer
TE3 - A randomised multi-centred phase 3 study of infusional versus bolus bleomycin in IGCCCG good prognosis metastatic non-seminoma.

This is the major recruiting Orchid study in testis cancer. To date more than 160 patients have been recruited from 7 sites.

GAMIO in relapsed germ cell tumours of the testis.

A new study (GAMIO) is open and taking forward the team's work in the group of poor prognosis relapsed germ cell tumours. This study builds on the findings of GAMEC and incorporates PET as an early surrogate marker of response.

- Prostate cancer

A randomised phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer.

The team are taking forward the recent publication on the use of chemotherapy in the absence of androgen ablation in castrate resistant prostate cancer. Getting this study up and running has taken time and resources. The study will get regulatory approval in 2008, involve 4 sites and be the major clinical thrust of our work prostate clinical work in 2009.

PPAR agonists in castration –resistant prostate cancer in patients failing maximum androgen blockade.

This ongoing study using PSA velocity as an endpoint aims to establish the role of rosiglitazone and fenofibrate in a group of patients with rising PSA who are asymptomatic.

A titration study of Evorel (transdermal estradiol) in castration- resistant, dexamethasone resistant prostate cancer.

This ongoing study uses plasma estradiol sampling to determine any threshold effect and dose response effect for this agent.

The use of melphalan and whole blood stem cell support.

This ongoing study started to recruit in 2007. Lenograstim (GCSF) primed peripheral blood (which is rich in stem cells) is venesected. The patients receive melphalan in a dose escalation study. The blood will be returned to the patient the next day, and should lead to rapid regeneration of blood count, allowing the melphalan to be given every 14 days rather than the usual 28–42 days. During this study blood sampling for circulating tumour cells and endothelial progenitor cells (in collaboration with the department of Haematology) are to be undertaken.

Dr Yong-Jie Lu
Senior Lecturer
Molecular Oncology & Imaging,
Institute of Cancer BLSMD,
Queen Mary, University of London Charterhouse Square London

Grant aims

The main aim of this programme is to identify novel genetic alterations in male urological tumours and to investigate their clinical impact using the approach from whole genome screening to identify candidate genes down to functional study of individual genes. The main activities can be split into three areas:

1. Following the success in applying high resolution SNP array analysis in micro/macrodisectioned prostate cancer samples, the team continued to apply a genome-wide analysis approach to identify candidate genes in prostate cancer development and progression. This research aim was specifically selected as the team is based at a well-equipped research centre for cancer genetic study with Professor Bryan Young at the front, driving the application of new genomic technologies. This approach also reflects the PI's expertise. The aim of

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

the study was to identify novel genetic markers for further investigation for their clinical application in cancer prevention, diagnosis, prognosis and novel forms of therapies.

2. From our previous genome-wide analysis of testicular germ cell tumours (TGCTs), we identified a commonly deleted 6q25 region containing an under-expressed gene *ZDHHC14*. In this year, the team is aiming to confirm the tumour suppressor role of *ZDHHC14* in both TGCTs and prostate cancer, including its clinical prevalence and functional roles.

3. From the team's previous TGCT cisplatin resistant expression microarray data, it was identified that *CCND1/cyclinD1* was the most significantly differentially expressed gene when comparing parental and resistant cell lines. The final study in TGCT chemoresistance this year was to prove that *CCND1* is the gene that causes cisplatin resistance in TGCTs.

Key achievements

1. A project grant application submitted to AICR was awarded (190K for 3 years) to investigate the tumour suppressor role of *ZDHHC14* in TGCTs and prostate cancer.

2. 33 pairs of Chinese prostate cancer samples and case-matched normal controls have been analysed using SNP array 6.0 and striking differences between western and Chinese prostate cancer was revealed including lack of deletions of *PTEN* and 21q23 in Chinese prostate cancer.

3. FISH analysis of t(4;6) chromosome translocation was completed on the large cohort of the TAPG (TransAtlantic Prostate Group) early stage cancers in the format of 24 tissue microarray (TMA) sections (900 cases).

4. The team carried out immunohistochemistry analysis of six seminoma, four non-seminoma, one prostate cancer and one benign prostate hyperplasia (BPH) TMA sections and revealed the significantly reduced expression of *ZDHHC14* in seminoma cells.

5. *CCND1* overexpression was identified as the major genetic alteration associated with cisplatin resistance in TGCTs, ovarian and prostate cancers and knocking-down of the *CCND1* using siRNA sensitises cells to cisplatin in the Susa cisplatin resistant (SusaR) TGCT cell line and PC3 prostate cancer cell line.

6. The team established the long range PCR method to be used with the new generation sequencing technology to sequence the candidate genes identified in this programme.

7. First Orchid funded PhD student (Elodie Noel) completed her study successfully and was awarded PhD degree.

Progress of the project

The major achievements in this year are summarised below:

1. Genome-wide analysis of genomic alterations in Chinese prostate cancer

A project grant from the MRC was awarded to study chromosome rearrangements and fusion genes in prostate cancer, including the SNP array analysis of the UK prostate cancer samples. As the team have the opportunity to access a prostate cancer fresh frozen tissue bank through the collaboration with a Chinese consultant histopathologist Professor Yongwei Yu, therefore, the planned SNP array analysis in the Orchid programme was directed to study the Chinese samples, in order to have a better understanding of the similarities and/or differences of somatic genomic changes occurring in prostate cancer cells between western and Chinese samples. We applied the most recently developed Affymetrix array 6.0 chips with 1.8 million SNP and copy number variation probes to study 33 Chinese prostate cancer samples with case-matched adjacent normal controls. 10 prostate cancer samples, 6 with and 4 without matched normal tissue from UK were also studied using the same approach. Cancer cells were macro- or microdissected to achieve an >85% purity. The microarray data were analysed by our in house software GOLF and the recently released commercially available microarray analysis software, Partek.

DNA copy number changes in the 33 Chinese prostate cancer samples was carried out to provide a high-resolution genomic alteration profile. Compared with our UK cancer samples, the genomic copy number changes in the Chinese samples are fewer (average 15.8 versus 11.3 per sample). The common genomic changes are gains of 7q and 8q, and losses of 5q, 6q, 8p, 13q and 16q which were also frequently seen in western prostate cancers. Interestingly, the team found the Chinese cancer samples lack two of the common genomic changes existing in western samples – losses of 10q and 21q. The 10q deletion leads to the inactivation of the *PTEN* gene located on 10q23.3 and the 21q deletion causes the *TMPRSS2:ERG* fusion gene. In the 33 Chinese prostate cancer samples, the team found 10q deletion covering the *PTEN* gene in 2

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

cases and did not find any 21q deletion covering the region from *ERG* to *TMPRSS2*. The team's samples are pure enough to detect the genomic changes as shown on the other chromosome regions and the analysis system we used was able to detect the deletion at 10q *PTEN* region and 21q22.2 region between *ERG* to *TMPRSS2* as shown in 5 and 8 of the 10 UK samples respectively. This finding indicates that deletion of 10q *PTEN* region and the 21q22.2 between *TMPRSS2* and *ERG* may be the major genomic alterations underlying the regional/ethnic incidence difference of prostate cancer and that they may be induced by the specific environmental and/or genetic risk factors exposed to the western men.

Completion of the t(4;6) FISH analysis of the large TAPG cohort of prostate cancers

Using the improved FISH technique and the Ariol image scan and processing system, we completed the FISH analysis of all the 24 TMA sections of Prof. Cuzick's TAPG collection of early stage prostate cancers. Out of the 2612 informative cases (a minimum of 50 cells containing both green and red signals), it was found that 297 (11.4%) cores with t(4;6) translocation based on counting co-localisation signals and positive defined as >10% co-localisation signals. In 3 TMAs, the chromosome 4 and 6 probe co-localisation positive samples were confirmed by signal splitting analysis using only chromosome 6 probes located either side of the breakpoints. The FISH data has been submitted to Professor Cuzick's team for statistic analysis aiming to assess the prognostic value of t(4;6) in prostate cancer.

Investigation of *ZDHHC14* as a putative tumour suppressor gene

In previous years the team identified the high frequency deletion of *ZDHHC14* genomic region in TGCTs and under-expression in TGCTs and prostate cancer. Within this year, the team validated the polyclonal rabbit antibody against human *ZDHHC14* by Western blotting (Fig 3A) and used it for immunohistochemistry analysis. *ZDHHC14* was expressed in the cytoplasm, positive in spermatocytes and Sertoli cells and very strongly expressed in Leydig cells (Fig 3B). We analysed six seminoma and four non-seminoma TMA sections using immunohistochemistry for *ZDHHC14* expression (Table 1). *ZDHHC14* is significantly under-expressed in seminomas comparing with morphologically normal seminiferous tubules adjacent to the cancers ($P < 0.01$). However, in non-seminomas, due to the mixed tissue types, *ZDHHC14* staining is not uniform within tissue cores and the data is difficult to interpret. Although the trend of down-regulation of *ZDHHC14* can be seen (Table 1), it is not statistically different from the adjacent normal controls ($P = 0.11$) which can be due to the limited number of control cases. The team also carried out initial immunohistochemistry analysis of one prostate and one BPH TMAs. Within the prostate gland, basal cells are strongly stained, but *ZDHHC14* expression both in the luminal epithelial cells of the PBH samples and in the cancer cells varies and no conclusion can be drawn due to the limited number of samples. Further analysis is required. To functionally investigate the role of *ZDHHC14* in tumourigenesis, the team analysed the role of *ZDHHC14* in cell migration. Having optimised a *ZDHHC14* siRNA transfection protocol, the gene expression was knocked down using a custom designed Dharmacon SMARTpool in the prostate cancer cell line PC3, and the immortalised prostate epithelial cell line PNT1A. A nontargeting siRNA was used as negative control and knock-down of an ubiquitously expressed Lamin was performed as a positive control. The knock-down efficiency was confirmed at the RNA level by Q-RT-PCR. Transwell migration analysis showed that knocking down of *ZDHHC14* resulted in significantly increased cell migration (Fig 4).

CCND1/Cyclin D1 overexpression and cisplatin resistance

In the previous year, the team completed the planned TGCT cisplatin resistance study. Before moving away from this study to focus on prostate cancer research, the microarray data of the three pairs of cisplatin sensitive and resistant TGCT cell lines was reviewed using new bioinformatics tools. The team identified *CCND1*, the oncogene controlling cycle cell G1/S transition, which was not implicated in our initial 2-fold change criteria, as significantly overexpressed in the resistant cell lines. In the Susa pair, there was an 8-fold difference between the resistant and the sensitive cell lines. Therefore, we extended this study to investigate the importance of *CCND1* overexpression in cisplatin resistant TGCTs and other cancers.

Firstly, these results were confirmed by Q-RT-PCR analysis in the three pairs of cell lines and then the team continued to investigate the expression of *CCND1* in TGCT clinical samples, and finding the *CCND1* expression was significantly higher in resistant cases compared to sensitive samples. To examine the team's findings in other cisplatin resistant tumours, some ovarian and prostate cancers were analysed, and the team found that *CCND1* expressed dozens of fold higher in the resistant than in the sensitive ovarian cancer cell lines and over-expressed dramatically in prostate cancer, a type of tumour that is generally resistant to cisplatin. Finally, the team sensitised the resistant cells in SusaR and PC3 cell lines to cisplatin by knocking-down *CCND1* using siRNA. (Please see the attached relevant manuscript for details regarding to *CCND1/Cyclin D1* overexpression and cisplatin resistance.)

The team also established a long range PCR method which can amplify 7-8kb human genomic DNA. This will be used with the new generation sequencing technology for sequencing analysis of the candidate genes identified from our genome-wide analysis. The whole genomic region of *CCND1* gene in the three pairs of cisplatin sensitive and resistant TGCT cell lines has been amplified using this method for sequencing analysis.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

Fundraising

Incoming resources for the year totalled £1,008,954 against the 2007/08 total of £1,301,428. Income from individuals has fallen on the previous year following receipt of the final instalment of £500,000 from a major benefactor. This was expected and measures to replace the income were put in place during the year. These measures resulted in strong performance in key areas, particularly within the events programme. The introduction of new events, an increase in the number of supporters' organising their own events and better awareness of Orchid's work have contributed to this performance. Income from trusts and grant making bodies and support from the business community has also increased.

The following information summarises the various disciplines:

- Donations. Excluding the annual donation from a major benefactor, income from general donations increased by 6% on the previous year due in part to an increased number of in-memoriam gifts. A major donor development programme was launched at the Fleming Gallery, Mayfair in March. Progress has been slower than expected given the current economic climate and further work in this area is needed in the year ahead.
- Events. Income from the events programme has been the most successful to date with an increase of 40% on the previous year. Orchid has maintained its investment in places and promotion in the London, New York, Chicago and Berlin World Marathon Majors, and secured a healthy return on investment. For next year, more emphasis will be put on targeting own place runners, whilst extending our presence in the new running events, Run to the Beat and The Royal Parks Half Marathons. Below is a summary of the income from Orchid's fundraising events:
 - The ninth annual charity bike ride, OrchidCycle Essex, was the most successful ever raising over £44,000 from 762 participants, a substantial increase from the 2008 event.
 - Orchid organised its first bespoke trek to Kilimanjaro in June raising over £70,000.
 - The second New Forest bike ride took place in September with over 1100 participants raising £36,000 in sponsorship.
 - Orchid bought 25 places in Run to the Beat Half Marathon and participants raised over £10,000. A team of 30 took part in the Royal Parks Half Marathon and raised over £17,000.
 - Marathons continue to raise much needed funds for Orchid - 35 runners in the 2009 Flora London Marathon raised £89,000, a team of 10 took part in the ING New York Marathon raising over £23,000 and 6 runners in the Berlin Marathon raised over £4,000.
 - Orchid's many friends and supporters continue to organise a wide range of events and have raised over £253,000. Among the highlights were The Regis Classic Tour, the Cottesmore Golf Day, a Dinner hosted by the England rugby player Jason Leonard, and three Balls held in London, Windsor and Huddersfield between them raising over £100,000.
- Corporate Relations. Income from the business community has increased by 20% on the previous year reflecting the good relationships and partnerships the charity has developed with individual companies. We were especially pleased to become the chosen Charity of the Year for King Sturge LLP and Hammonds, London Office and have been working with staff to organise events, awareness days and fundraising activities. Other companies who chose to support Orchid during the year include hi-fi retail specialist Richer Sounds, The British Prostate Centre, online retailer Prezzybox.com, clothing company Raging Bull and Moto, the UK's largest provider of Motorway Service Areas. We are extremely grateful for the continued support of the following companies - Paperchase, Austin Reed, Anytime After Nine, British Gas and NEXT, the latter of whom launched Orchid branded boxer shorts as part of a Father's Day initiative.

Matched giving schemes remain an invaluable source of income and we appreciate the numerous companies that operate them to encourage their staff to our ultimate benefit.
- Grants :Trust and Foundations Income from grant making bodies increased by 45% on the previous year reflecting the appointment of a Trusts and Statutory Fundraising Manager and a more focussed

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

approach to submitting applications, closer engagement with current and prospective supporters and a more structured evaluation process. The strategy focuses on developing new business and building longer-term partnerships to ensure the sustainability of future services, in particular the role of a dedicated nurse. We are grateful for the continued support of grant-making trusts and foundations, in particular, The GW Bulmer Charitable Trust, The Isle of Man Anti-Cancer Association and The Light Fund.

FINANCIAL REVIEW

Investment Policy

The Trustee's policy is to hold funds on deposit with HSBC, Birmingham Midshires and the Charity Aid Foundation and COIF Charity banks.

Results for the Year

Incoming resources for the period totalled £1,008,954 (2007/08: £1,301,428). After a total expenditure of £1,102,787 (2007/08: £921,442), the period's activities show a net deficit of £93,833 (2007/08: surplus £379,986). Included in the total expenditure in 2008/09 is the award of the research grant of £520,000 for work to be carried out in 20010/11, which represented the charity's liability for that commitment.

Reserves Policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £1,250,000 towards future research grant awards. The level of funds retained reflects the trustees' aspiration to co-fund a Chair of Oncology in the Barts & London School of Medicine, whilst no commitment was made in 2008/9 it is anticipated that a commitment of £500,000 will be required in 2009/10, while ensuring that programmes currently funded will continue to be supported beyond the current commitment, subject to the feedback from the independent peer review process.

Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensures that the Charity's core activity of funding research and awareness during a period of unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available reserves net of tangible fixed assets are approximately £261,325 (2007/08: £359,406). This represents approximately 3-4 months of operating costs at current levels and provides resources to fund the organisational restructure recently agreed by the Board. This is above and beyond activity to which the charity is legally committed, or funds that have been otherwise specifically restricted or designated.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

FUTURE PLANS

Building on the achievements of the previous year and following a review of the external environment and trends the following goals have been identified for 2009/10:

Research

- Orchid is dedicated to supporting men affected by male cancer through a programme of high quality research. Advised by the Scientific Advisory Board, we aim to continue to fund research which helps improve our understanding of male cancer and works towards improving treatment and management techniques for patients.
- Orchid aims to work with funding partners with the objective of appointing the Chair of Male Genito-Urinary Oncology.
- Orchid aims to identify opportunities to attract young researchers and/ or healthcare professionals into the area of male cancer.

Education and Awareness

- Orchid aims to appoint a specialist nurse to support the development and delivery of information products, to respond to enquiries from people affected by or interested in male cancer and to develop strategic partnerships with healthcare professionals, social care professionals, employers, voluntary organisations and community groups.
- Orchid provides practical and emotional help to people affected by or interested in male cancer via the telephone, email, printed information and online. We aim to increase distribution of printed information by 20%. We will work towards securing Department of Health accreditation as a mark of quality for information products
- Orchid aims to continue developing a programme of specialist services for people affected by or interested in penile cancer.
- Orchid aims to increase awareness of its work and male cancer amongst healthcare professionals and education professionals. To this end we aim to increase our mailing database by 25%.
- Orchid aims to complete and implement the re-build of its website and a dedicated testicular cancer site ensuring increased interactivity in all areas. We aim to increase website visitors by 10%.
- Orchid aims to develop campaign and media activities including the Orchid Male Cancer Awareness Week to further raise awareness of male cancer and the charity.

Fundraising

- Orchid will continue to secure funding from a range of sources to meet its commitments and long term objectives.

Staff and volunteers

- Orchid is committed to the management, training and personal development of its staff and volunteers. We aim to introduce a formal staff appraisal system, annual staff awayday, learning and training programme and ensure staff and volunteers are fully informed and engaged in the organisations strategy and objectives.

THE ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 June 2009

FORMAL STATEMENTS

Statement of Trustees' Responsibilities

The trustees (who are also directors of The Orchid Cancer Appeal for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming/outgoing resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditors' Information

So far as each of the directors at the time the trustees' report is approved is aware:

- a) there is no relevant information of which the auditors are unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The auditors, Kingston Smith LLP, are deemed reappointed auditors in accordance with provisions of the Companies Act 2006.

Kingston Smith LLP has indicated their willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that they be re-appointed auditors for the ensuing year.

The accounts have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Charities Statement of Recommended Practice (SORP 2005) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees.



23 February 2010

R S Broadhurst Esq CBE
Chairman of Trustees

THE ORCHID CANCER APPEAL

AUDITORS REPORT TO THE MEMBERS OF THE ORCHID CANCER APPEAL

For the year ended 30 June 2009

We have audited the financial statements of The Orchid Cancer Appeal for the year ended 30 June 2009 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. The financial statements have been prepared under the accounting policies set out therein.

This report is made solely to the charitable company's members, as a body, in accordance with Sections 495 and 496 of the Companies Act 2006. Our audit work has been undertaken for no purpose other than to draw to the attention of the charitable company's members those matters which we are required to include in an auditor's report addressed to them. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors

The trustees' (who are also the directors of the company for the purpose of company law) responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and for being satisfied that the financial statements give a true and fair view are set out in the Statement of Trustees' Responsibilities.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view, have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, and have been prepared in accordance with the Companies Act 2006. We also report to you whether in our opinion the information given in the Trustees' Annual Report is consistent with those financial statements.

In addition we report to you if, in our opinion, the charitable company has not kept adequate accounting records, if the charitable company's financial statements are not in agreement with the accounting records and returns, if we have not received all the information and explanations we require for our audit, or if certain disclosures of trustees' remuneration specified by law are not made.

We read the Trustees' Annual Report and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of audit opinion


We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to the charitable company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion:

- the financial statements give a true and fair view of the state of the charitable company's affairs as at 30 June 2009, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- the financial statements have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
- the financial statements have been properly prepared in accordance with the Companies Act 2006; and
- the information given in the Trustees' Annual Report is consistent with the financial statements.


Sandra De Lord, Senior Statutory Auditor
For and on behalf of Kingston Smith LLP, Statutory Auditor
Devonshire House,
60 Goswell Road,
London
EC1M 7AD

Date: 24 February 2010

THE ORCHID CANCER APPEAL

STATEMENT OF FINANCIAL ACTIVITIES

For the year ended 30 June 2009

	Note	Unrestricted Funds £	Restricted Funds £	TOTAL 2009 £	TOTAL 2008 £
INCOMING RESOURCES					
Incoming Resources from Generated Funds					
Voluntary Income					
Donations & Gifts		151,658	78,500	230,158	638,975
Activities for Generating Funds					
Events Income		636,049	-	636,049	478,123
Other Income		13,129	-	13,129	32,207
Investment Income		<u>129,618</u>	<u>-</u>	<u>129,618</u>	<u>152,123</u>
Total Incoming Resources		930,454	78,500	1,008,954	1,301,428
RESOURCES EXPENDED					
Cost of Generating Funds					
Fundraising Costs		291,553	-	291,553	211,523
Charitable Activities					
Research		520,192	55,700	575,892	530,697
Education & Awareness		189,093	20,300	209,393	146,654
Governance		<u>25,949</u>	<u>-</u>	<u>25,949</u>	<u>32,568</u>
Total Resources Expended	2	<u>1,026,787</u>	<u>76,000</u>	<u>1,102,787</u>	<u>921,442</u>
Net (Expenditure) /Income		(96,333)	2,500	(93,833)	379,986
Total Funds Brought Forward		1,984,406	-	1,984,406	1,604,420
Total Funds Carried Forward		<u>1,888,073</u>	<u>2,500</u>	<u>1,890,573</u>	<u>1,984,406</u>

There were no recognised gains or losses other than those shown in the above statement of financial activities. The results for the above financial periods derive from continuing operations.

THE ORCHID CANCER APPEAL

BALANCE SHEET


As at 30 June 2009

	Notes	2009		2008	
		£	£	£	£
FIXED ASSETS					
Tangible Assets	6		1,748		1,994
CURRENT ASSETS					
Cash at Bank and in Hand		3,176,764		3,059,604	
Other debtors	7	<u>214,539</u>		<u>119,942</u>	
		3,391,303		3,179,546	
CREDITORS					
Amount falling due within one year	8	<u>982,478</u>		<u>694,271</u>	
NET CURRENT ASSETS			<u>2,408,825</u>		<u>2,485,275</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			2,410,573		2,487,269
CREDITORS					
Amount falling in greater than one year	9		520,000		502,863
NET ASSETS			<u>1,890,573</u>		<u>1,984,406</u>
REPRESENTED BY					
Accumulated Funds					
Restricted Funds	10		2,500		-
Designated Funds	10	1,625,000		1,625,000	
General Unrestricted Funds	10	<u>263,073</u>		<u>359,406</u>	
			<u>1,888,073</u>		<u>1,984,406</u>
			<u>1,890,573</u>		<u>1,984,406</u>

The company is limited by guarantee.

The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board on 8 December 2009 and authorised for issue on 23 February 2010 and signed on its behalf by:



Mr R J O Barton



Mr R S Broadhurst

THE ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2009

1. ACCOUNTING POLICIES

The accounts have been prepared under the historical cost convention and in accordance with the Statement of Recommended Practice "Accounting and Reporting by Charities" SORP 2005, the Companies Act 2006 and applicable accounting standards in the United Kingdom. A summary of the more important accounting policies, which have been applied consistently, is set out below.

Cash Flow

The accounts do not include a cash flow statement because the charity, as a small reporting entity, is exempt from the requirement to prepare such a statement under Financial Reporting Standards 1 'Cash Flow Statements.'

Taxation

No corporation tax is provided for, as the company, being a charity, is exempt. Due to its current activities the charity is not registered for VAT and therefore cannot recover VAT on its expenses.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment	33 1/3% on written down value
-------------------------------	-------------------------------

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal. The purpose and use of the charity's restricted funds is set out in the notes to the financial statements.

Incoming Resources

All incoming resources becoming available to the company during the year are included when there is entitlement to the income, certainty of receipt and amounts can be measured with sufficient reliability.

Resources Expended

Cost of generating funds includes costs associated with the fund-raising events in furtherance of the charity's objects.

Charitable Expenditure includes costs associated with particular activities in furtherance of the charity's objects.

Governance costs are those incurred in connection with the management of the charity's assets, organisational administration, and compliance with constitutional and statutory requirements.

Charitable expenditure and governance costs comprise direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Pension Scheme

The charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the charity's contributions payable in the year. The assets of the scheme are held separately from the charity. There was no outstanding liability owed to the scheme at the end of the current or prior years

THE ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2009

2. TOTAL RESOURCES EXPENDED

	Cost of generating funds	Research	Education & Awareness	Governance	2009	2008
	£	£	£	£	£	£
Grants	-	536,097	-	-	536,097	489,591
Fundraising expenses	160,348	-	-	-	160,348	107,160
Information	-	-	13,921	-	13,921	29,530
Education & awareness	-	-	59,242	-	59,242	17,371
Audit fees	-	-	-	4,671	4,671	4,739
Other	-	-	-	1,492	1,492	1,711
	160,348	536,097	73,163	6,163	775,771	650,102
<i>Support costs</i>						
Staff costs	111,269	33,749	115,531	16,780	277,329	212,918
Depreciation	351	106	364	53	874	997
Other	19,585	5,940	20,335	2,953	48,813	57,425
	131,205	39,795	136,230	19,786	327,016	271,340
Total resources expended	291,553	575,892	209,393	25,949	1,102,787	921,442

No trustee received any remuneration during the period (2008: nil). One trustee received reimbursement of expenses of £161 (2008: three - £1,499).

3. GRANTS AWARDED

	2009	2008
	£	£
Grant commitments brought forward	1,152,396	1,373,474
Institutional grants for medical research awarded during year	545,000	502,863
Net write back of grants	(8,902)	(13,272)
Payments made during year	<u>(527,059)</u>	<u>(710,669)</u>
Grant commitments carried forward	<u>1,161,434</u>	<u>1,152,396</u>
Payable less than one year	641,434	649,533
Payable two to five years	<u>520,000</u>	<u>502,863</u>

4. TAXATION

Orchid is a registered charity and as such its income and gains are exempt from corporation tax to the extent that they are applied to its charitable objectives. There is no corporation tax charge for the year.

THE ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2009

5. EMPLOYEES

The average number of employees during the year was 8 (2008: 6)

	2009	2008
	£	£
Wages and Salaries	248,660	192,360
Social Security Costs	26,401	20,558
Employer pension costs	2,268	546
Total staff costs	<u>277,329</u>	<u>213,464</u>

No employee earned over £60,000 (2008: one employee earned £70,000-£80,000).

6. TANGIBLE ASSETS

	2009	2008
	£	£
Computer and Office Equipment		
COST		
At 1 July 2008	15,692	15,692
Additions	628	-
At 30 June 2009	<u>16,320</u>	<u>15,692</u>
DEPRECIATION		
At 1 July 2008	13,698	12,701
Charge for the period	874	997
At 30 June 2009	<u>14,572</u>	<u>13,698</u>
NET BOOK VALUE		
At 30 June 2009 /2008	<u>1,748</u>	<u>1,994</u>

7. DEBTORS

	2009	2008
	£	£
Prepayments	64,199	59,696
Other debtors and accrued income	<u>150,340</u>	<u>60,246</u>
	<u>214,539</u>	<u>119,942</u>

THE ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2009

8. LIABILITIES: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2009	2008
	£	£
Grants payable	641,434	649,533
Trade & Other Creditors	315,965	36,440
Taxation and Social Security	6,167	328
Accruals	18,912	7,970
	<u>982,478</u>	<u>694,271</u>

9. LIABILITIES: AMOUNTS FALLING DUE IN GREATER THAN ONE YEAR

	2009	2008
	£	£
Grants payable	<u>520,000</u>	<u>502,863</u>
	<u>520,000</u>	<u>502,863</u>

10. FUNDS

	Brought Forward £	Income £	Expenditure £	Transfers £	Carried forward £
Unrestricted					
General	359,406	930,454	1,026,787	-	263,073
Designated – Research	1,250,000	-	-	-	1,250,000
Designated – Development	225,000	-	-	-	225,000
Designated – Awareness	150,000	-	-	-	150,000
	<u>1,984,406</u>	<u>930,454</u>	<u>1,026,787</u>	<u>-</u>	<u>1,888,073</u>
Restricted					
Research	-	55,700	55,700	-	-
Information Dissemination	-	22,800	20,300	-	2,500
	<u>-</u>	<u>78,500</u>	<u>76,000</u>	<u>-</u>	<u>2,500</u>
Total Restricted	<u>-</u>	<u>78,500</u>	<u>76,000</u>	<u>-</u>	<u>2,500</u>
Total Funds	<u>1,984,406</u>	<u>1,008,954</u>	<u>1,102,787</u>	<u>-</u>	<u>1,890,573</u>

Restricted funds are represented by cash.

THE ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2009

10. FUNDS (continued)

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the charity and which have not been designated for other purposes.

Designated Research fund represent monies set aside at the Trustees' discretion to be used to help fund the costs of research programmes in the future.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

Restricted funds represent monies specifically raised to fund specific research programmes or information dissemination and have been fully expended in the period.

11. RELATED PARTY TRANSACTIONS

There were no related parties during the year.